Edoxaban. Domenico Prisco Dipartimento di Medicina Sperimentale e Clinica Università di Firenze SOD Patologia Medica, AOU Careggi, Firenze
|
|
- Gerard Briggs
- 5 years ago
- Views:
Transcription
1 Edoxaban Domenico Prisco Dipartimento di Medicina Sperimentale e Clinica Università di Firenze SOD Patologia Medica, AOU Careggi, Firenze Bologna 8 novembre 2013 Disclosures: DP has received research support and honoraria by GSK, Bayer, Daiichi Sankyo, BMS, Boehringer Ingelheim
2 What does the name Edoxaban mean? EDO Xa BAN 2
3 Features of novel oral anticoagulants Dabigatran 1 Rivaroxaban 1,2 Apixaban 1,3 Edoxaban 4 6 Target IIa (thrombin) Xa Xa Xa Hours to Cmax CYP metabolism None 32% Minimal <4% Bioavailability 6% 80% 60% 62% Transporters P gp P gp/bcrp P gp/ BCRP P gp Protein binding 35% 93% 87% 50% Half life h (BD) 7 11 h (QD/BD) 8 15 h (BD) 8 10 h (QD) Renal elimination 80%* 33% # 25% # 35% # BCRP, breast cancer resistance protein CYP, cytochrome P450; P-gp, P-glycoprotein NR, not reported * Of absorbed substance # Of ingested substance 1. Eriksson et al. Clin Pharmacokinet 2009;48:1-22; 2. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2011; 3. ELIQUIS Summary of Product Characteristics. Bristol Myers Squibb/Pfizer EEIG, UK; 4. Ruff et al. Hot Topics in Cardiology 2009;18:1-32; 5. Matsushima et al. Am Assoc Pharm Sci 2011; abstract; 6. Ogata et al. J Clin Pharmacol 2010;50:743-53
4 A single 60 mg dose of edoxaban inhibits thrombin generation for >24 hours in HV 40 Mean change from baseline thrombin (mean ± SD) (A) Edoxaban (B) Enoxaparin Time (Hours Post Dose) Mendell J et al. The effect of administration of edoxaban with enoxaparin or 12 hours post-enoxaparin on the pharmacokinetics, pharmacodynamics, and tolerability of edoxaban. Presented at 21 st International Congress on Thrombosis; Jul 6-9, 2010; Milan
5 Phase II data Atrial Fibrillation
6 Edoxaban study 018: Dose Finding Study in Atrial Fibrillation Study design: Randomized, double blind edoxaban dose regimens, open label warfarin, parallel treatment groups Primary Objective: Evaluation of safety of four fixed dose regimens of Edoxaban vs. Warfarin in patients with atrial fibrillation (CHADS 2 2) Primary endpoints: Occurrence of major and/or clinically relevant non major bleeding, elevated hepatic enzymes and/or bilirubin Edoxaban 30 mg QD Edoxaban 60 mg QD Screening Edoxaban 30 mg BID Edoxaban 60 mg BID* Follow up assessment N= days Day 1 Active control (Warfarin, INR ) 3 month randomized treatment period +30 days after last dose *Stopped prematurely QD, once daily; BID, twice daily; INR, International Normalized RatioWeitz et al. Thromb Haemost 2010;104:
7 Edoxaban study 018: major and clinically relevant non major bleeding 12 ** Bleeding incidence (%) * 0 Warfarin Edoxaban 30 mg QD Edoxaban 60 mg QD Edoxaban 30 mg BID Edoxaban 60 mg BID n/n 8/250 7/235 11/234 19/244 19/180 *p<0.05, **p<0.01, vs warfarin QD, once daily; BID, twice daily Weitz et al. Thromb Haemost 2010;104:633-41
8 Edoxaban phase II dose finding study in atrial fibrillation: exposure and bleeding C max AUC C min ng/ml Ng*h/mL ng/ml QD 60 QD 30 BID 60 BID 30 QD 60 QD 30 BID 60 BID 0 30 QD 60 QD 30 BID 60 BID AUC, area under the plasma concentration-time curve from 0 to 24 hours at steady-state; C max, maximum steady-state plasma concentration; C min, minimum steady-state concentration; QD, once daily; BID, twice daily Bleeding incidence, % QD Edoxaban 60 QD 30 BID 60 BID Weitz et al. Thromb Haemost 2010;104:633-41
9 C min,ss is best predictor of bleed probability Probability of all bleeds mg QD 60 mg QD 30 mg BID 60 mg BID AUC, area under the plasma concentration-time curve from 0 to 24 hours at steady-state C max, maximum steady-state plasma concentration C min, minimum steady-state concentration P-gp, P-glycoprotein PRT-018 observed C max AUC C min Predicted incidence C min,ss most closely matched observed bleeding 1,2 Clinical trial simulations of bleeding incidence were used to select 30 mg and 60 mg oncedaily edoxaban with 50% dose reductions for patients with moderate renal impairment or receiving concomitant strong P-gp inhibitors in the ENGAGE AF-TIMI 48 trial 2 1. Giugliano RP et al. Presented at ISTH congress 2009, Boston, USA 2. Salazar et al. Thromb Haemost 2012;107. Epub ahead of print
10 Impact of renal impairment and concomitant P glycoprotein inhibitors on edoxaban exposure C min,ss ratio 50% 20% Increase in exposure CL CR 80 ml/min CL CR 50 ml/min CL CR 30 ml/min Keto, ketoconazole; Quin, quinidine; Ery, erythromycin; Amio, amiodarone; Verap, verapamil; CL CR, creatinine clearance; C min, ss, trough concentration at steady state. Salazar et al. Thromb Haemost 2012;107:
11 Simulation of dosage adjustment scenarios for Phase III subpopulations Without dose adjustment With dose adjustment 0.14 Incidence of all bleeding events All bleeds rate in warfarin group 0.00 Base 60 mg Renal Verap Ren+Ver Renal Verap Ren Ver 60 mg od 30 mg od **Horizontal yellow line denotes observed all bleeds rate in NCT (study 018, dose finding) warfarin group od, once daily Salazar et al. Thromb Haemost 2012;107:
12 Edoxaban Phase III development programme VTE prophylaxis orthopaedic surgery Stroke prevention in atrial fibrillation VTE Treatment / secondary prophylaxis JAPAN / ASIA GLOBAL GLOBAL
13 HOKUSAI VTE Great Wave at Kanagawa. Katsushika Hokusai (25.4 x 37.1 cm) color woodblock print from Hokusai's series Thirty-six Views of Mount Fuji, which are the high point of Japanese prints. The Hokusai-VTE Investigators. N Engl J Med 2013 Hokusai-VTE clinical study protocol. Version 5.0, 16 April Daiichi Sankyo
14
15 N=8, sites in 37 countries Hokusai VTE: study design Randomized, double blind, event driven study Edoxaban 60 mg (30 mg) * Objectively confirmed VTE Stratified randomization: DVT / PE Dose of edoxaban Risk factors R Sham INR INR All patients followed for 12 months regardless of treatment duration Day 1 5 Day 6 12 Warfarin (INR ) 3 mo 12 mo Edoxaban Placebo Edoxaban Warfarin Placebo Warfarin Low molecular weight heparin / UFH *Dose was halved to 30 mg in patients perceived to be at higher risk for bleeding due to potential overanticoagulation by predefined criteria During days 6 12 edoxaban or placebo edoxaban was started once heparin was stopped Raskob et al. J Thromb Haemost 2013;11: The Hokusai-VTE Investigators. N Engl J Med 2013
16 Dosing regimens in Hokusai VTE Edoxaban dose was 60 mg once daily with or without food Edoxaban dose was halved to 30 mg once daily with or without food At randomization: Permanent: CrCl ml/min Body weight 60 kg Temporary: Concomitant potent P gp inhibitor use, only while on these medications: quinidine, verapamil During study: Permanent: CrCl ml/min and >20% drop from baseline Body weight 60 kg and >10% drop from baseline Temporary: Concomitant potent P gp inhibitor use, only while on these medications: quinidine, verapamil, erythromycin, azithromycin, clarithromycin, ketoconazole, itraconazole The Hokusai-VTE Investigators. N Engl J Med 2013 Hokusai-VTE clinical study protocol. Version 5.0, 16 April Daiichi Sankyo
17 Flexible treatment duration Prior to study start investigators chose a target length of therapy based on guidelines 1 Study start Minimum treatment period After 3 months, proposed treatment period could be varied by investigator based on patient s clinical features: risk of recurrent VTE, risk of bleeding, patient s preference 2 3 months >3 12 months 1. Hokusai VTE clinical study protocol. Version 5.0, 16 April Daiichi Sankyo Inc 2. Raskob et al. J Thromb Haemost 2013;11:
18 Efficacy and safety outcome measures Primary efficacy: symptomatic recurrent VTE Defined as composite of DVT, non fatal or fatal PE during the 12 month period Principal safety: clinically relevant bleeding Defined as composite of major or clinically relevant nonmajor bleeding during treatment or within 3 days of stopping or interrupting study treatment All primary efficacy and principal safety outcomes were adjudicated by a Clinical Events Committee Raskob et al. J Thromb Haemost 2013;11:
19 Inclusion criteria Inclusion criteria Adult ( 18 years) patients presenting with acute symptomatic DVT involving the popliteal, femoral or iliac veins, or acute symptomatic PE, or both, confirmed by appropriate diagnostic imaging Raskob et al. J Thromb Haemost 2013;11: The Hokusai VTE Investigators. N Engl J Med 2013
20 Characteristic Mean age (years±sd) Age 75 years, n (%) Overall patient characteristics Edoxaban (N=4118) 55.7± (13.6) Warfarin (N=4122) 55.9± (13.2) Male sex, n (%) 2360 (57.3) 2356 (57.2) Weight, n (%) 60 kg >60 kg >100 kg Creatinine clearance, n (%) ml/min >50 ml/min Patients dosed with 30 mg edoxaban (or placebo) at randomization, n (%) Race, n (%) Caucasian Asian Black or African American Other SD=standard deviation 524 (12.7) 3594 (87.3) 611 (14.8) 268 (6.5) 3850 (93.5) 519 (12.6) 3603 (87.4) 654 (15.9) 273 (6.6) 3849 (93.4) 733 (17.8) 719 (17.4) 2867 (69.6) 866 (21.0) 156 (3.8) 220 (5.3) 2895 (70.2) 861 (20.9) 144 (3.5) 215 (5.2) The Hokusai-VTE Investigators. N Engl J Med 2013;
21 Characteristic Overall patient characteristics (cont.) Causes of DVT or PE, n (%) Unprovoked Temporary risk factor * History of cancer Active cancer Previous VTE Actual duration of treatment with study drug, n (%) 3 months >3 to 6 months >6 months 12 months Edoxaban (N=4118) 2713 (65.9) 1132 (27.5) 378 (9.2) 109 (2.6) 784 (19.0) 485 (11.8) 1076 (26.1) 2557 (62.1) 1661 (40.3) Warfarin (N=4122) 2697 (65.4) 1140 (27.7) 393 (9.5) 99 (2.4) 736 (17.9) 528 (12.8) 1084 (26.3) 2510 (60.9) 1659 (40.2) Duration of study drug, mean days±sd / median 250.3±111.8 / ±112.6 / 261 Total patient years on study drug Total patient years of follow up off study drug * Temporary risk factors include: recent surgery, trauma, immobilization or estrogen use SD=standard deviation The Hokusai-VTE Investigators. N Engl J Med 2013;
22 Treatment The median duration of heparin treatment after randomization was 7 days Overall treatment duration was similar between the two groups 250.3±111.8 days (mean±sd) for edoxaban treated patients 248.4±112.6 days for warfarin treated patients Adherence to edoxaban was 80% in 99% of patients as measured by pill counts The INR was in the therapeutic range for 63.5% of the time, above 3.0 for 17.6% of time, and below 2.0 for 18.9% of time The Hokusai-VTE Investigators. N Engl J Med 2013
23 Kaplan Meier curves of efficacy outcomes overall analysis Edoxaban Warfarin Overall On Rx TTR : 63.5% Number at Risk: Edoxaban Overall Warfarin Overall Edoxaban On-tx Warfarin On-tx The Hokusai-VTE Investigators. N Engl J Med 2013
24 Primary efficacy outcome (recurrent VTE) Outcome All patients, n (%) Overall study period On treatment period Edoxaban (N=4118) 130 (3.2) 66 (1.6) Warfarin (N=4122) 146 (3.5) 80 (1.9) Patients with index DVT, n (%) 2468 (59.9) 2453 (59.5) Overall study period On treatment period 83 (3.4) 48 (2.0) 81 (3.3) 50 (2.0) Patients with index PE, n (%) 1650 (40.1) 1669 (40.5) Overall study period On treatment period 47 (2.8) 18 (1.1) 65 (3.9) 30 (1.8) Relative risk (95% CI) 0.89 ( ) * 0.82 ( ) * 1.02 ( ) 0.96 ( ) 0.73 ( ) 0.60 ( ) * P<0.001 for non inferiority The Hokusai-VTE Investigators. N Engl J Med 2013
25 Efficacy outcomes Subgroup analysis: 30 mg # Characteristic Edoxaban (N=733) Warfarin (N=719) Relative risk (95% CI) Efficacy Recurrent VTE 22 (3.0) 30 (4.2) 0.73 ( ) # At randomization and for overall (12-month) treatment period regardless of treatment duration The Hokusai-VTE Investigators. N Engl J Med 2013
26 Cumulative Event Rate (%) Kaplan Meier curves of principal safety Edoxaban Warfarin outcome Time to Event (days) Number of patients at risk warfarin edoxaban The Hokusai-VTE Investigators. N Engl J Med 2013
27 Principal safety outcomes Patients (%) HR 0.81, 95% CI, P=0.004 for superiority HR 0.80, 95% CI, % P=0.004 for superiority 8.5% 8.9% 7.2% HR 0.84, 95% CI, P=0.35 for superiority 1.4% 1.6% The Hokusai-VTE Investigators. N Engl J Med 2013
28 Other safety outcomes Outcome Adverse events, n (%) Any treatment emergent event Any serious adverse event (SAE) Any SAE leading to permanent discontinuation Any drug related AE leading to permanent discontinuation Death, n (%) overall study period VTE related Myocardial infarction Ischemic stroke Other cardiac death Cancer Infectious disease Other Edoxaban (N=4118) 2821 (68.5) 503 (12.2) 121 (2.9) 41 (1.0) 132 (3.2) Warfarin (N=4122) 2928 (71.0) 544 (13.2) 105 (2.5) 51 (1.2) 126 (3.1) The Hokusai-VTE Investigators. N Engl J Med 2013; Daiichi Sankyo, data on file.
29 Cardiovascular events On treatment period, n (%) Edoxaban (N=4118) Warfarin (N=4122) Acute coronary event Cerebrovascular event Systemic embolism 20 (0.5) 26 (0.6) 4 (<0.1) 13 (0.3) 26 (0.6) 0 (0.0) 30 day post study treatment period Edoxaban (N=4061) Warfarin (N=4077) Acute coronary event Cerebrovascular event Systemic embolism 1 (<0.1) 2 (<0.1) 1 (<0.1) 3 (<0.1) 8 (0.2) 2 (<0.1) The Hokusai-VTE Investigators. N Engl J Med 2013
30 Liver function tests On treatment period, n (%) Edoxaban n/n (%) Warfarin n/n (%) ALT 3x ULN 81/3901 (2.1) 90/3903 (2.3) ALT 5x ULN 26/3901 (0.7) 28/3903 (0.7) ALT or AST 3x ULN + bilirubin 2x ULN 9/3878 (0.2) 4/3865 (0.1) ALT or AST 3x ULN+ concurrent bilirubin 2x ULN 6/3878 (0.2) 3/3865 (<0.1) Number of subjects with events satisfying Hy s Rule per adjudication (pure drug effect) 0/3878 2/3865 (<0.1) Liver failure 0/4118 1/4122 ALT=alanine transaminase; AST=aspartate transaminase; ULN=upper limit of normal The Hokusai-VTE Investigators. N Engl J Med 2013
31 Safety outcomes Subgroup analysis: 30 mg Characteristic Safety Primary: First major or clinically relevant non major bleeding, n (%) Edoxaban (N=733) Warfarin (N=719) Relative risk (95% CI) 58 (7.9) 92 (12.8) 0.62 ( ) Major bleeding, n (%) 11 (1.5) 22 (3.1) 0.50 ( ) Clinically relevant non major bleeding, n (%) 47 (6.4) 70 (9.7) The Hokusai-VTE Investigators. N Engl J Med 2013
32 Subgroup of patients with pulmonary embolism
33 Primary efficacy outcome (recurrent VTE) HR= % CI P<0.001 * 3.5% 3.2% HR= % CI % 3.3% HR= % CI % HR= % CI P<0.001 * 1.6% 1.9% HR= % CI %2.0% 2.8% HR= % CI % 1.1% * for non-inferiority The Hokusai-VTE Investigators. N Engl J Med 2013; e-pub ahead of print
34 Subgroup analysis in PE patients with NT probnp 500 pg/ml HR=0.52 (95% CI, ) 6.2% 3.3% 15/454 30/484 The Hokusai-VTE Investigators. N Engl J Med 2013
35 Subgroup analysis in Hokusai VTE Approximately 90% of PE patients had a baseline NT probnp level measured In PE patients with NT probnp levels 500 pg/ml recurrent VTE occurred in 15 of 454 patients (3.3%) who received edoxaban and in 30 of 484 patients (6.2%) given warfarin (HR 0.52 [ ]) Of the 1002 random sample of patients measured by CT, approximately 35% had RV dysfunction Similar results were observed in patients with RV dysfunction on CT as in those with NT probnp levels 500 pg/ml (HR 0.42 [ ]) The Hokusai-VTE Investigators. N Engl J Med 2013
36 NOAC VTE trials: Anatomic extent of qualifying PE EINSTEIN PE 1 AMPLIFY 2 Hokusai VTE 3 Patients with PE ± DVT, n Anatomic extent of qualifying PE, n (%) Limited: 25% of vasculature of a single lobe 608 (13) 168 (9) 251 (8) Intermediate 2816 (58) 787 (43) 1361 (41) Extensive: 2 lobes with 25% of entire vasculature 1173 (24) 683 (37) 1521 (46) Not assessable 235 (5) 198 (11) 186 (6) Dabigatran RE COVER trial anatomic extent of qualifying PE not reported Extensive: 2 lobes with 50% of vasculature for each lobe 1. EINSTEIN PE Investigators. N Engl J Med 2012;366: Agnelli et al. N Engl J Med doi: /nejmoa The Hokusai-VTE Investigators. N Engl J Med 2013
37 Edoxaban 60 mg regimen: Conclusions Non inferior to standard therapy for preventing recurrent VTE Statistically significant reduction of clinically relevant bleeding Results consistent across a broad range of patients including: those receiving patient specific dosing with 30 mg edoxaban patients with severe PE The Hokusai-VTE Investigators. N Engl J Med 2013
38 Unique study features Hokusai VTE Largest single study in VTE Once daily dosing Dynamic dose adjustment Flexible treatment duration (3 12 months) Simulate usual clinical practice Active INR feedback to sites regarding TTR Follow up of all patients for 12 months Primary efficacy analysis at 12 months regardless of duration of therapy Raskob et al. J Thromb Haemost 2013; e pub ahead of print Daiichi Sankyo Inc. Data on file
39 Study design N=21,105 AF on electrical recording < 12 mo Intended oral anticoagulant CHADS 2 > 2 R Low exposure strategy: edoxaban 30 mg QD High exposure strategy: edoxaban 60 mg QD Median duration of follow up 24 months Active control: warfarin (INR ) Primary objective Edoxaban: therapeutically as good as warfarin 1º endpoint = stroke or SEE (non inferiority boundary HR 1.38) 2º endpoint = stroke or SEE or all cause mortality Safety endpoints = major bleeding, hepatic function AF, atrial fibrillation, mo, months; QD, once daily; HR, hazard ratio SEE, systemic embolic event; INR, International Normalized Ratio Ruff et al. Am Heart J 2010;160:
40 Patients randomized to either of the two edoxaban groups anticipated to have an increased drug exposure received a 50% dose reduction (e.g. from 30 mg to 15 mg) Dose reductions occurred for one or more of the following: CrCl ml/min calculated with the Cockcroft Gault formula Body weight 60 kg Dosing strategy Concomitant administration of strong P gp inhibitors: verapamil, quinidine, or dronedarone Dose reduction can occur at randomization or any time during the trial CrCl, creatinine clearance; P gp, P glycoprotein Ruff et al. Am Heart J 2010;160:
41 End of Study Transition 1. Detailed protocol amendment, training 2. Required transition to open label A/C, unless absolute contraindication 3. Transition permitted to VKA or NOAC 4. If transitioning to open label VKA Transition Kit containing active edoxaban given until INR therapeutic Frequent INR testing (> 3) in first 2 weeks Use of approved VKA dosing algorithm req.
42 Baseline Characteristics in AF Trials RE-LY (Dabigatran) ARISTOTLE (Apixaban) ENGAGE AF-TIMI 48* (Edoxaban) ROCKET-AF (Rivaroxaban) # enrolled 18,113 18,201 21,105 14,264 Age (yrs) 72 ± 9 70 [63-76] 72 [64-77] 73 [65-78] Female 36% 35% 38% 40% CHADS 2 score 3 32% 30% 52% 87% VKA naive 50% 43% 41% 38% Paroxysmal AF 33% 15% 25% 18% Prior stroke/tia 20% 19% 18% / 12% 55%** Diabetes 23% 25% 36% 40% Prior CHF 32% 35% 56% 62% Hypertension 79% 87% 90% 91% *Preliminary data **includes prior systemic embolism Patel MR, et al. N Engl J Med 2011;Aug 10:[Epub] Connolly SJ, et al. N Engl J Med 2009;Aug 30:[Epub] Granger CB, et al. N Engl J Med 2011 (doi /NEJMoa )
43 Phase III AF trials: dose comparisons RE-LY ROCKET-AF ARISTOTLE ENGAGE AF-TIMI 48 Drug Dabigatran Rivaroxaban Apixaban Edoxaban N 18,113 14,266 18,201 21,105 Dose (mg) 150, , 30 Frequency BID QD BID QD Initial Dose adj* No mg mg mg mg Dose adj (%) >25 Dose adj* after randomization No No No Yes Design PROBE 2x blind 2x blind 2x blind *Dose adjusted in patients with drug clearance, low body weight, concomitant p gp inhibitors PROBE, prospective randomized, open label, blinded end point evaluation Connolly et al. N Engl J Med 2009;361: Patel et al. N Engl J Med 2011;365: Granger et al. N Engl J Med 2011;365:
44 Edoxaban in Atrial Fibrillation What Will It Add to Current Knowledge? 1. The largest (21,105) RCT in AF with a NOAC with the longest follow up (median 2.8 yrs) 2. Two once daily dosing regimens (60 & 30 mg) 3. First study with continually dose adjustment (60 30 mg; mg) at and after randomization providing data on 3 doses spanning a 4 fold range 4. Benefit of hindsight: Minimizing missing data Transition on/off edoxaban/oacs Warfarin titration Wealth of ancillary studies exploring disease state, pharmacology and mechanism of action
45 Clinical Experience To date, over 34,000 subjects enrolled in the edoxaban clinical program Phase I: ~ 870 subjects Phase II DVT/VTE prophylaxis: ~1750 subjects Phase II Atrial Fibrillation: ~1500 subjects Phase III DVT/VTE prophylaxis: ~1300 subjects Phase III DVT/VTE treatment: ~8000 subjects Phase III Atrial Fibrillation: ~21,000 subjects
Engage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationResults from Hokusai-VTE presented during ESC Congress 2013 Hot Line session and published in the New England Journal of Medicine
Press Release Daiichi Sankyo s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationDaiichi Sankyo s Once-Daily Lixiana
Daiichi Sankyo s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationEdoxaban: The newest NOAC option for stroke prevention in AF
Edoxaban: The newest NOAC option for stroke prevention in AF Dr. Paul Angaran, MD FRCPC Cardiac Electrophysiologist St. Michael s Hospital, Toronto February 11, 2017 Disclosures Relationships with commercial
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION Edoxaban (Lixiana SERVIER Canada Inc.) Indication: Prevention of Stroke and Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationOral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationInsufficienza renale e DOAC
Insufficienza renale e DOAC Domenico Prisco DMSC, Università di Firenze SOD Patologia Medica, AOU Careggi Bologna 14 ottobre 2014 Ha ricevuto onorari per relazioni e partecipazione ad advisory board e
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationFibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali
Fibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali Gianluca Botto, MD, FAAC, FESC Divisione di Cardiologia Ospedale Sant Anna, Como The Promise of NOAs Antithrombotic
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationNewer Anti-Anginal Agents and Anticoagulants
Newer Anti-Anginal Agents and Anticoagulants Satish Gadi, MD FACC FSCAI Interventional Cardiologist, Cardiovascular Institute of the South (CIS) Baton Rouge Clinical Assistant Professor, Tulane University
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationDuration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationKelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY
Jedi Training 101: Mind-tricks & Evidence -Based Approaches to Combating Clinical Controversies in Anticoagulation Therapy Kelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY LEARNING
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationΑντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη Σταύρος Β. Κωνσταντινίδης, MD, PhD, FESC Καθηγητής Καρδιολογίας Δημοκρίτειο Πανεπιστήμιο Θράκης skonst@med.duth.gr Medical Director
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationKeynote lecture: Oral anticoagulation and DVT
Keynote lecture: Oral anticoagulation and DVT What is the evidence? Is there a need to anticoagulate every lower leg DVT? Disclosure Speaker name:...sebastian Schellong... I have the following potential
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationNew Anticoagulants and Emerging Strategies
New Anticoagulants and Emerging Strategies in the Treatment of Venous Thromboembolism b Stavros V. Konstantinides, MD, PhD, FESC Head, Department of Cardiology, Democritus University of Thrace, Greece
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationNew oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials
New oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials Dimitri Richter, MD, FESC, FAHA Head of Cardiac Dept., Athens Euroclinic General Secretary of Hellenic Lipidology Society Member
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationDisclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationABSTRACT INTRODUCTION
Adv Ther (2014) 31:473 493 DOI 10.1007/s12325-014-0119-7 REVIEW Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More information